Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Apr 1.

Published in final edited form as: Biomaterials. 2011 Feb 1;32(11):3141–3149. doi: 10.1016/j.biomaterials.2011.01.017

Table 3.

Improved anti-prion efficacy of PLL.

	Anti-prion activity

	ScN2a cells^a	PMCA^b
LL	7.36 mM	1 mM^c
PLL50	15 nM	0.6 µM
Efficacy improved	5 × 10⁵ fold	1.6 × 10³ fold

^a

The IC₅₀ of LL and PLL50 represent the anti-prion activity in ScN2a cells.

^b

The concentrations of LL and PLL50 that abrogated plasminogen-mediated PrP conversion represent the anti-prion activity in PMCA.

^c

Adopted from [18].